Skip to main content
OpenTrials
Completed

NCT Number: NCT00350857

The Young Adult and Pediatric Bipolar Study

To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

10 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

11 Shire Clinical Research Site, Altamonte Springs, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Key Inclusion Criteria:
  • DSM-IV diagnosis of bipolar I disorder, most recent episode manic or mixed.
  • A lifetime history of bipolar disorder symptoms for at least 2 months.
  • YMRS score greater than or equal to 16.
  • CGI-S score greater than or equal to 4.
  • Male or female outpatient aged between 10-17 years old inclusive at the time of consent.
  • Functioning at an age-appropriate level intellectually, as deemed by the Investigator.
  • The subject has no co-morbid illness that could affect efficacy, safety, or tolerability or in any way interfere with the subject's participation in the study.
  • Must have a satisfactory medical assessment with no clinically significant and relevant abnormalities.

Exclusion criteria

  • Key Exclusion Criteria:
  • Current controlled or uncontrolled, co-morbid psychiatric diagnosis that could interfere with clinical assessments or study conduct.
  • A history of lack of therapeutic response or hypersensitivity to the study drug.
  • A greater than or equal to 50% reduction in YMRS between Screening and Baseline.
  • Acutely at risk for suicidal or violent behavior or a history of suicide attempts requiring medical intervention.
  • A history of aplastic anemia, agranulocytosis or bone marrow depression.
  • A history of seizure disorder, other than a single childhood febrile seizure.
  • A history of severe, unstable asthma.
  • Current hospitalization for psychiatric symptoms.
  • History of alcohol or other substance abuse or dependence.
  • Pregnant or lactating females.
  • Body weight less than or equal to 25 kg.

Treatment and study plan

Extended-release carbamazepine

Drug

Primary outcomes

  1. Safety and tolerability as assessed by the occurrence of treatment emergent adverse events and evaluations of clinical laboratory values, physical examinations, vital signs and ECG data after 6 months of treatment.

    Time frame: 6 months

Secondary outcomes

  1. Reduction of bipolar symptoms as assessed by the Young Mania Rating Scale (YMRS), Clinical Global Impressions Scale (CGI) and Children's Depression Rating Scale (CDRS-S) after 6 months of treatment.

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Validus Pharmaceuticals

Industry

Registry information

Official study title

A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder.

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Jul 11, 2006
Registry last updated
Feb 20, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.